PARP Inhibitors In BRCA-Mutated Breast Cancer

Published on

Topics include: Treatments

PARP inhibitors are an effective therapeutic option for BRCA-mutated ovarian cancer patients, but how do they stack up against BRCA-mutated breast cancer? Dr. Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in breast cancer, highlights the results of a study presented at ESMO 2017 about PARP inhibitors used in this patient population.

This interview was recorded at the European Society of Medical Oncology (ESMO) congress held in Madrid (September 2017). Breast cancer videos recorded at ESMO 17 are part of an educational program by the Patient Empowerment Foundation (PEF). We thank Roche for their support.

View more programs featuring

Related Programs

How Can Genomic Profiling Benefit Breast Cancer Patients?

What is the role of genomic profiling in breast cancer? Dr. Giuseppe Curigliano explains why genomic profiling can be beneficial to patients.


What Are the Main Subtypes of Breast Cancer?

What are the four subtypes of breast cancer? Dr. Giuseppe Curigliano explains the subtypes and which treatment is best for each type.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on September 25, 2017